These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

272 related articles for article (PubMed ID: 16465192)

  • 21. [Angiogenesis and renal cell carcinoma].
    Billemont B; Méric JB; Izzedine H; Taillade L; Sultan-Amar V; Rixe O
    Bull Cancer; 2007 Jul; 94 Spec No():S232-40. PubMed ID: 17846009
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Impact of the incorporation of tyrosine kinase inhibitor agents on the treatment of patients with a diagnosis of advanced renal cell carcinoma: study based on experience at the Hospital Universitario Central de Asturias.
    Muriel C; Esteban E; Corral N; Fonseca PJ; Luque M; Berros JP; Fernández Y; Blay P; Fra J; Villanueva N; Sanmamed M; Pardo P; Izquierdo M; Vieitez JM; Estrada E; Lacave ÁJ
    Clin Transl Oncol; 2010 Aug; 12(8):562-7. PubMed ID: 20709657
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Arterial hypertension and clinical benefit of sunitinib, sorafenib and bevacizumab in first and second-line treatment of metastatic renal cell cancer.
    Ravaud A; Sire M
    Ann Oncol; 2009 May; 20(5):966-7; author reply 967. PubMed ID: 19403939
    [No Abstract]   [Full Text] [Related]  

  • 24. [Angiogenesis inhibitors for the systemic treatment of metastatic renal cell carcinoma: sunitinib, sorafenib, bevacizumab and temsirolimus].
    de Mulder PH; Haanen JB; Sleijfer S; Kruit WH; Gietema JA; Richel DJ; Groenewegen G; Voest EE; van den Eertwegh AJ; Osanto S; Jansen RL; Mulders PF
    Ned Tijdschr Geneeskd; 2008 Feb; 152(7):371-5. PubMed ID: 18380383
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sorafenib and sunitinib: novel targeted therapies for renal cell cancer.
    Grandinetti CA; Goldspiel BR
    Pharmacotherapy; 2007 Aug; 27(8):1125-44. PubMed ID: 17655513
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Medical treatment of metastatic renal cell carcinoma after the approval and market entry of multitargeted tyrosine kinase inhibitors in Germany].
    Bolenz C; Trojan L; Honeck P; Schöppler G; Herrmann E; Alken P; Michel MS; Häcker A
    Aktuelle Urol; 2009 Jan; 40(1):31-6. PubMed ID: 19177319
    [TBL] [Abstract][Full Text] [Related]  

  • 27. VEGF-targeted therapy in renal cell carcinoma: active drugs and active choices.
    Rini BI
    Curr Oncol Rep; 2006 Mar; 8(2):85-9. PubMed ID: 16507216
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Systemic therapy for metastatic renal cell carcinoma.
    Kroog GS; Motzer RJ
    Urol Clin North Am; 2008 Nov; 35(4):687-701; ix. PubMed ID: 18992622
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeted treatment for metastatic renal cell carcinoma and immune regulation.
    Laschos KA; Papazisis KT; Kontovinis LF; Kalaitzis C; Gianakopoulos S; Kortsaris AH; Touloupidis S
    J BUON; 2010; 15(2):235-40. PubMed ID: 20658715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Trials probe new agents for kidney cancer.
    Hampton T
    JAMA; 2006 Jul; 296(2):155-7. PubMed ID: 16835411
    [No Abstract]   [Full Text] [Related]  

  • 31. [Novelties in the treatment for advanced renal-cell cancer].
    Maráz A
    Orv Hetil; 2011 Apr; 152(17):655-62. PubMed ID: 21464023
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sunitinib, sorafenib, temsirolimus or bevacizumab in the treatment of metastatic renal cell carcinoma: a review of health economic evaluations.
    Norum J; Nieder C; Kondo M
    J Chemother; 2010 Apr; 22(2):75-82. PubMed ID: 20435564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular biology of renal cell carcinoma.
    Mellado B; Gascón P
    Clin Transl Oncol; 2006 Oct; 8(10):706-10. PubMed ID: 17074668
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical efficacy and prognostic factors for overall survival in Japanese patients with metastatic renal cell cancer treated with sunitinib.
    Yuasa T; Tsuchiya N; Urakami S; Horikawa Y; Narita S; Inoue T; Saito M; Yamamoto S; Yonese J; Fukui I; Nakano K; Takahashi S; Hatake K; Habuchi T
    BJU Int; 2012 May; 109(9):1349-54. PubMed ID: 21883864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Major treatment improvements encourage kidney cancer researchers to seek further gains.
    Tuma RS
    J Natl Cancer Inst; 2008 Sep; 100(17):1202-3. PubMed ID: 18728277
    [No Abstract]   [Full Text] [Related]  

  • 36. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
    Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
    BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Antitumor effects of sunitinib or sorafenib in patients with metastatic renal cell carcinoma who received prior antiangiogenic therapy.
    Tamaskar I; Garcia JA; Elson P; Wood L; Mekhail T; Dreicer R; Rini BI; Bukowski RM
    J Urol; 2008 Jan; 179(1):81-6; discussion 86. PubMed ID: 17997441
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Anti-angiogenic treatment in the management of metastatic renal cell carcinoma].
    Sire M; Wallerand H; Kilkoski F; Grenier N; Ferrière JM; Ravaud A
    Bull Cancer; 2008 Sep; 95(9):813-20. PubMed ID: 18829413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Targeted therapies in metastatic renal cell carcinoma: the light at the end of the tunnel.
    Pouessel D; Culine S
    Expert Rev Anticancer Ther; 2006 Dec; 6(12):1761-7. PubMed ID: 17181490
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surgical morbidity associated with administration of targeted molecular therapies before cytoreductive nephrectomy or resection of locally recurrent renal cell carcinoma.
    Margulis V; Matin SF; Tannir N; Tamboli P; Swanson DA; Jonasch E; Wood CG
    J Urol; 2008 Jul; 180(1):94-8. PubMed ID: 18485389
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.